A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors
Clinical trial NCT07684261 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07684261
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-07-20
- Primary completion
- 2028-12-31
- Enrollment
- 186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.